Skip to main content
. 2012 Dec 10;31(3):359–364. doi: 10.1200/JCO.2012.44.4711

Fig 4.

Fig 4.

Survival after recurrence for patients relapsing (A) within the first 18 months after study entry and (B) relapsing 18 months after study entry. HR, hazard ratio; mFF6, modified fluorouracil, leucovorin, and oxaliplatin for 6 months; mFF6 + Bev, mFF6 for 6 months plus bevacizumab for 12 months.